PT  - JOURNAL ARTICLE
AU  - Wang, Si-Han
AU  - Tang, Yu-Hsuan
AU  - Hsu, Hao
AU  - Yu, Chu-Nien
AU  - Leea, Oscar Kuang-Sheng
TI  - Identification of targets for drug repurposing to treat COVID-19 using a Deep Learning Neural Network
AID  - 10.1101/2023.05.23.23290403
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.23.23290403
4099  - http://medrxiv.org/content/early/2023/05/29/2023.05.23.23290403.short
4100  - http://medrxiv.org/content/early/2023/05/29/2023.05.23.23290403.full
AB  - The COVID-19 pandemic has resulted in a global public health crisis requiring immediate acute therapeutic solutions. To address this challenge, we developed a useful tool deep learning model using the graph-embedding convolution network (GECN) algorithm. Our approach identified COVID-19-related genes and potential druggable targets, including tyrosine kinase ABL1/2, pro-inflammatory cytokine CSF2, and pro-fibrotic cytokines IL-4 and IL-13. These target genes are implicated in critical processes related to COVID-19 pathogenesis, including endosomal membrane fusion, cytokine storm, and tissue fibrosis. Our analysis revealed that ABL kinase inhibitors, lenzilumab (anti-CSF2), and dupilumab (anti-IL4Rα) represent promising therapeutic solutions that can effectively block virus-host membrane fusion or attenuate hyperinflammation in COVID-19 patients. Compared to the traditional drug screening process, our GECN algorithm enables rapid analysis of disease-related human protein interaction networks and prediction of candidate drug targets from a large-scale knowledge graph in a cost-effective and efficient manner. Overall, Overall, our results suggest that the model has the potential to facilitate drug repurposing and aid in the fight against COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Ministry of Science and Technology [Grant numbers MOST 110-2314-B-A49A-504-MY3, MOST 110-2926-I-010-504, MOST 108-2923-B-010-002-MY3, MOST 109-2823-8-010-003-CV, MOST 109-2622-B-010-006, MOST 110-2321-B-A49A-502, and MOST 110-2923-B-A49A-501-MY3]; the Development and Construction Plan of the School of Medicine, National Yang-Ming University, now known as National Yang Ming Chiao Tung University [Grant number 107F-M01-0504]; Aiming for the Top University Plan, a grant from the Ministry of Education [Grant number MOST 109-2823-8-010-003-CV]. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data supporting the findings of this study are available from the corresponding author upon reasonable request.